AndrÃ©s D Klein

List of Publications by Year
in descending order

32 papers	1,201 citations	471509 17 h-index	414414 32 g-index
33 all docs	33 docs citations	33 times ranked	1962 citing authors

#	Article	IF	Citations
1	Genetic Background Matters: Population-Based Studies in Model Organisms for Translational Research. International Journal of Molecular Sciences, 2022, 23, 7570.	4.1	4
2	Lack of Annexin A6 Exacerbates Liver Dysfunction and Reduces Lifespan of Niemann-Pick Type C Proteinâ€“Deficient Mice. American Journal of Pathology, 2021, 191, 475-486.	3.8	3
3	Proteomic Analysis of Niemann-Pick Type C Hepatocytes Reveals Potential Therapeutic Targets for Liver Damage. Cells, 2021, 10, 2159.	4.1	9
4	Identification of genetic modifiers of murine hepatic Î²-glucocerebrosidase activity. Biochemistry and Biophysics Reports, 2021, 28, 101105.	1.3	4
5	Role of proteases in dysfunctional placental vascular remodelling in preeclampsia. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165448.	3.8	11
6	c-Abl Inhibition Activates TFEB and Promotes Cellular Clearance in a Lysosomal Disorder. IScience, 2020, 23, 101691.	4.1	30
7	Complement Component C3 Participates in Early Stages of Niemannâ€“Pick C Mouse Liver Damage. International Journal of Molecular Sciences, 2020, 21, 2127.	4.1	9
8	Integrin Alpha E (CD103) Limits Virus-Induced IFN-I Production in Conventional Dendritic Cells. Frontiers in Immunology, 2020, 11, 607889.	4.8	1
9	Modeling Parkinsonâ€™s Disease Heterogeneity to Accelerate Precision Medicine. Trends in Molecular Medicine, 2019, 25, 1052-1055.	6.7	6
10	Rare diseases in Chile: challenges and recommendations in universal health coverage context. Orphanet Journal of Rare Diseases, 2019, 14, 289.	2.7	20
11	Gadolinium Chloride Rescues Niemannâ€“Pick Type C Liver Damage. International Journal of Molecular Sciences, 2018, 19, 3599.	4.1	4
12	Is Parkinsonâ€™s disease a lysosomal disorder?. Brain, 2018, 141, 2255-2262.	7.6	124
13	Controversies on the potential therapeutic use of rapamycin for treating a lysosomal cholesterol storage disease. Molecular Genetics and Metabolism Reports, 2018, 15, 135-136.	1.1	12
14	Modeling diseases in multiple mouse strains for precision medicine studies. Physiological Genomics, 2017, 49, 177-179.	2.3	5
15	Delineating pathological pathways in a chemically induced mouse model of Gaucher disease. Journal of Pathology, 2016, 239, 496-509.	4.5	54
16	Brain Disorders Due to Lysosomal Dysfunction. Annual Review of Neuroscience, 2016, 39, 277-295.	10.7	129
17	Identification of Modifier Genes in a Mouse Model of Gaucher Disease. Cell Reports, 2016, 16, 2546-2553.	6.4	52
18	Reduced ceramide synthase 2 activity causes progressive myoclonic epilepsy. Annals of Clinical and Translational Neurology, 2014, 1, 88-98.	3.7	50

#	Article	IF	Citations
19	RIPK3 as a potential therapeutic target for Gaucher's disease. Nature Medicine, 2014, 20, 204-208.	30.7	147
20	The unique case of the Niemann-Pick type C cholesterol storage disorder. Pediatric Endocrinology Reviews, 2014, 12 Suppl 1, 166-75.	1.2	10
21	Disruption in Connexin-Based Communication Is Associated with Intracellular Ca2+ Signal Alterations in Astrocytes from Niemann-Pick Type C Mice. PLoS ONE, 2013, 8, e71361.	2.5	33
22	Lysosomal storage disorders: old diseases, present and future challenges. Pediatric Endocrinology Reviews, 2013, 11 Suppl 1, 59-63.	1.2	12
23	Neuronal and epithelial cell rescue resolves chronic systemic inflammation in the lipid storage disorder Niemann-Pick C. Human Molecular Genetics, 2012, 21, 2946-2960.	2.9	42
24	Lysosomal vitamin E accumulation in Niemannâ€“Pick type C disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2012, 1822, 150-160.	3.8	27
25	Complement is dispensable for neurodegeneration in Niemann-Pick disease type C. Journal of Neuroinflammation, 2012, 9, 216.	7.2	36
26	Cholinergic Abnormalities, Endosomal Alterations and Up-Regulation of Nerve Growth Factor Signaling in Niemann-Pick Type C Disease. Molecular Neurodegeneration, 2012, 7, 11.	10.8	24
27	Lack of Activation of the Unfolded Protein Response in Mouse and Cellular Models of Niemann-Pick Type C Disease. Neurodegenerative Diseases, 2011, 8, 124-128.	1.4	11
28	Npc1 deficiency in the C57BL/6J genetic background enhances Niemannâ€“Pick disease type C spleen pathology. Biochemical and Biophysical Research Communications, 2011, 413, 400-406.	2.1	41
29	Oxidative stress activates the c-Abl/p73 proapoptotic pathway in Niemann-Pick type C neurons. Neurobiology of Disease, 2011, 41, 209-218.	4.4	54
30	Anatomically Defined Neuron-Based Rescue of Neurodegenerative Niemannâ€“Pick Type C Disorder. Journal of Neuroscience, 2011, 31, 4367-4378.	3.6	90
31	Imatinib therapy blocks cerebellar apoptosis and improves neurological symptoms in a mouse model of Niemannâ€Pick type C disease. FASEB Journal, 2008, 22, 3617-3627.	0.5	86
32	NPC2 is expressed in human and murine liver and secreted into bile: Potential implications for body cholesterol homeostasis. Hepatology, 2006, 43, 126-133.	7.3	60